- Home
- Publications
- Publication Search
- Publication Details
Title
Axitinib plasma pharmacokinetics and ethnic differences
Authors
Keywords
Asian, Axitinib, Caucasian, Ethnic Factor, Pharmacokinetics
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 2, Pages 521-532
Publisher
Springer Nature
Online
2015-02-07
DOI
10.1007/s10637-015-0214-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
- (2014) Se-Hoon Lee et al. Asia-Pacific Journal of Clinical Oncology
- Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
- (2014) Y Wang et al. BRITISH JOURNAL OF CANCER
- Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
- (2014) Masatoshi Eto et al. CANCER SCIENCE
- Population pharmacokinetic analysis of axitinib in healthy volunteers
- (2013) May Garrett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Axitinib for the treatment of advanced renal cell carcinoma
- (2013) Hideyuki Akaza et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
- (2013) T. Ueda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
- (2012) Yazdi K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic evaluation of axitinib
- (2012) Brian Patson et al. Expert Opinion on Drug Metabolism & Toxicology
- Concise Drug Review: Pazopanib and Axitinib
- (2012) R. M. J. M. van Geel et al. ONCOLOGIST
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
- (2011) Kouichi Kurose et al. Drug Metabolism and Pharmacokinetics
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers
- (2011) Y. Chen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
- (2011) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Clinical Outcome and Prognostic Factors of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma in General Clinical Practice
- (2011) G. Tanigawa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
- (2010) Yazdi K. Pithavala et al. INVESTIGATIONAL NEW DRUGS
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
- (2010) Michael A. Tortorici et al. INVESTIGATIONAL NEW DRUGS
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
- (2010) Y. Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
- (2010) C. Yoo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
- (2009) Hailiang Zhang et al. BMC CANCER
- Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
- (2009) Y. K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Pharmacogenetics of Phase I and Phase II Drug Metabolism
- (2009) Severine Crettol et al. CURRENT PHARMACEUTICAL DESIGN
- A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
- (2009) H. Uemura et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
- (2009) Min Hee Hong et al. Cancer Research and Treatment
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started